**Supplement 4**

**Article Inclusion Criteria and Article Reviews**

Table 1 Cohort study inclusion criteria

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Criteria assessed | Criteria impact | Ideal criteria assessment | Good criteria assessment | Acceptable criteria assessment | Poor criteria assessment |
| Representativeness of the exposed cohort | High | Truly representative (comprehensive population sampling) | Somewhat representative | Selected group of users | No description provided |
| Selection of the non-exposed cohort | High | From the same community as the exposed cohort | From a different source to the exposed cohort | - | No description provided |
| Ascertainment of antidepressant use | High | Secure medical records (redeemed prescriptions or hospital records) or structured interview | Prescription given to the patient, but unconfirmed if redeemed | Other methods of ascertaining exposure | Written self-report; no description provided |
| Assessment of outcome | High | Independent blind assessment or record linkage (ICD codes or other hospital records) | - | Other methods of assessing outcome | Self-reported; no description provided |
| End of follow-up | Medium | All births (live and stillborn) and terminations | Births only (live and stillborn) | Live births only | No description provided |
| Study records the presence of depression and or anxiety in the unexposed cohort | Low | Yes | - | No; no description | - |
| Study records smoking | Low | Yes | - | No; no description | - |
| Study records alcohol use | Low | Yes | - | No; no description | - |
| Study records exposure to other medications | Low | Yes | - | No; no description | - |
| Study records other factors (e.g. maternal age) | Low | Yes | - | No; no description | - |

Cohort studies were tentatively included if relationship between the antidepressant usage during the first trimester of pregnancy and congenital heart defects could be measured. These potential studies then had individual criteria assessed.

For a cohort study to be included:

* The high impact criteria were overall ideal – one of these criteria could be good or acceptable, so long as the remaining high impact criteria were ideal.

AND

* The end of follow-up was not poor

AND

* At least one of the low impact criteria were ideal

Cohort studies were excluded if any of the high or medium impact criteria were poor.

Table 2 Case-control study inclusion criteria

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Criteria assessed | Criteria impact | Ideal criteria assessment | Good criteria assessment | Acceptable criteria assessment | Poor criteria assessment |
| Adequacy of the case definition | High | Independent blind assessment or record linkage | - | Other | Self-reported or no description |
| Representativeness of the cases | High | Consecutive or representative series of cases (i.e. all eligible cases over a defined period, in a specified area) | Potential for selection bias (non-consecutive selection) or acknowledged presence of biases | - | Not stated |
| Selection of the controls | High | Community controls (i.e. same community as the cases, and would be cases if they demonstrated the outcome of interest) | Hospital controls (from within the same community as the cases, but derived from a hospitalised population) | - | No description |
| Ascertainment of antidepressant use | High | Secure records (redeemed prescriptions or hospital records) or structured interview | Prescription given to the patient, but unconfirmed if redeemed | Other | Written self-report or no description |
| Same method of ascertainment for cases and controls | High | Yes | - | No description | No |
| Non-response rate | Low | Same rate for cases and controls | Non-respondents described | - | Rate different and no designation |
| Study records the presence of depression and or anxiety in the unexposed controls | Low | Yes | - | No; no description | - |
| Study records smoking | Low | Yes | - | No; no description | - |
| Study records alcohol use | Low | Yes | - | No; no description | - |
| Study records exposure to other medications | Low | Yes | - | No; no description | - |
| Study records other factors (e.g. maternal age) | Low | Yes | - | No; no description | - |

Case-control studies were tentatively included if the relationship between congenital heart defects and maternal usage of antidepressants during the first trimester of pregnancy could be measured. These potential studies then had individual criteria assessed.

For a case-control study to be included:

* The high impact criteria were overall ideal - one of these criteria could be good or acceptable, so long as the remaining high impact criteria were ideal.

AND

* At least two of the low impact criteria were ideal

Case-control studies were excluded if any of the high impact criteria were poor.

Table 3 Included cohort studies, reviewed by CDV

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study Reference | Jordan, et al. 2016 | Furu, et al. 2015 | Berard, et al. 2015 | Huybrechts, et al. 2014 | Ban, et al. 2014 | Vasilakis-Scaramozza, et al. 2013 | Margulis, et al. 2013 | Diav-Citrin, et al. 2008 | Oberlander, et al. 2008 | Davis, et al. 2007 | Kulin, et al. 1998 | Nordeng, et al. 2012 |
| Representativeness of the exposed cohort | Truly representative | Truly representative | Truly representative | Truly representative | Truly representative | Truly representative | Truly representative | Truly representative | Truly representative | Truly representative | Somewhat representative | Truly representative |
| Selection of the non-exposed cohort | From same community | From same community | From same community | From same community | From same community | From same community | From same community | From same community | From same community | From same community | From same community | From same community |
| Ascertainment of antidepressant use | Rx - maybe not dispensed | Secure records | Secure records | Secure records | Rx - maybe not dispensed | Rx - maybe not dispensed | Secure records | Structured interview | Secure records | Secure records | Structured interview | Structured interview |
| Assessment of outcome | Record linkage | Record linkage | Record linkage | Record linkage | Record linkage | Record linkage | Record linkage | Record linkage & structured interview | Independent blind assessment | Independent blind assessment | Record linkage | Record linkage |
| End of follow-up | Births and terminations | Live births only | Live births only | Live births only | Live births only | Births (live and stillborn) | Live births only | Live births only | Live births only | Live births only | Live births only | Births and terminations |
| Study records the presence of depression and or anxiety in the unexposed cohort | Yes | No description | Yes | Yes | Yes | No description | No | No | No description | No | No | Yes |
| Study records smoking | Yes | Yes | No | No description | Yes | Yes | Yes | Yes | No | No | yes | No |
| Study records alcohol use | No description | No | No | No description | No | No description | No | No | No | No | yes | No |
| Study records exposure to other medications | No description | Yes | Yes | No description | No | No description | Yes | Yes | No | No | No description | Yes |
| Study records other factors (e.g. maternal age) | Yes | Yes | Yes | No description | Yes | No description | Yes | Yes | Yes | Yes | yes | Yes |

Table 4 Included cohort studies, reviewed by SG

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study Reference | Jordan, et al. 2016 | Furu, et al. 2015 | Berard, et al. 2015 | Huybrechts, et al. 2014 | Ban, et al. 2014 | Vasilakis-Scaramozza, et al. 2013 | Margulis, et al. 2013 | Diav-Citrin, et al. 2008 | Oberlander, et al. 2008 | Davis, et al. 2007 | Kulin, et al. 1998 | Nordeng, et al. 2012 |
| Representativeness of the exposed cohort | Truly representative | Truly representative | Truly representative | Truly representative | Truly representative | Somewhat representative | Truly representative | Somewhat representative | Truly representative | Somewhat representative | Somewhat representative | Truly representative |
| Selection of the non-exposed cohort | From same community | From same community | From same community | From same community | From same community | From same community | From same community | From same community | From same community | From same community | From same community | From same community |
| Ascertainment of antidepressant use | Secure records | Secure records | Secure records | Secure records | Secure records | Secure records | Secure records | Structured interview | Secure records | Secure records | Structured interview | Structured interview |
| Assessment of outcome | Record linkage | Record linkage | Record linkage | Record linkage | Record linkage | Record linkage | Record linkage | Record linkage | Record linkage | Record linkage | Record linkage | Record linkage |
| End of follow-up | Births and terminations | Live births only | Live births only | Live births only | Live births only | Births and terminations | Live births only | Live births only | Live births only | Live births only | Births and terminations | Births and terminations |
| Study records the presence of depression and or anxiety in the unexposed cohort | No description | No description | Yes | Yes | Yes | No description | Yes | No | No | No | No | Yes |
| Study records smoking | No | Yes | No | No | Yes | Yes | Yes | Yes | No | No | Yes | No |
| Study records alcohol use | Yes | No | No | No | No | No | Yes | No | No | No | Yes | No |
| Study records exposure to other medications | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Yes |
| Study records other factors (e.g. maternal age) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |

Table 5 Included Case-Control Studies, reviewed by CDV

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Study Reference | Louik, et al. 2014 | Polen, et al. 2013 | De Jonge et al. 2013 | Alwan, et al. 2010 |
| Adequacy of the case definition | Independent blind assessment | Independent blind assessment | Independent blind assessment | Record linkage |
| Representativeness of the cases | Potential for biases | Consecutive / representative | Consecutive / representative | Not stated |
| Selection of the controls | Community controls | Community controls | Community controls | Community controls |
| Ascertainment of antidepressant use | Structured interview | Secure records | Secure records | Structured interview |
| Same method of ascertainment for cases and controls | Yes | Yes | Yes | Yes |
| Non-response rate | Non-respondents described | Rate diff. & no designation | Rate diff. & no designation | Same rate |
| Study records the presence of depression and or anxiety in the unexposed controls | No | No | No | No |
| Study records smoking | Yes | No | No | Yes |
| Study records alcohol use | No | No | No | Yes |
| Study records exposure to other medications | No | No | No | No |
| Study records other factors (e.g. maternal age) | Yes | Yes | Yes | Yes |

Table 5 Included Case-Control Studies, reviewed by SG

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Study Reference | Louik, et al. 2014 | Polen, et al. 2013 | De Jonge et al. 2013 | Alwan, et al. 2010 |
| Adequacy of the case definition | Record linkage | Consecutive / representative | Yes | Yes |
| Representativeness of the cases | Consecutive / representative | Community controls | Yes | Yes |
| Selection of the controls | Community controls | Structured interview | Yes | Yes |
| Ascertainment of antidepressant use | Structured interview | Record linkage | Structured interview | Structured interview |
| Same method of ascertainment for cases and controls | Yes | Yes | Yes | Yes |
| Non-response rate | Same rate | Rate diff. & no designation | Same rate | Same rate |
| Study records the presence of depression and or anxiety in the unexposed controls | No | No | No | No |
| Study records smoking | Yes | Yes | No | No |
| Study records alcohol use | Yes | Yes | No | No |
| Study records exposure to other medications | No | No Description | No | No |
| Study records other factors (e.g. maternal age) | Yes | Yes | Yes | Yes |

Table 6 Excluded Studies

| Author, Year | Cohort or Case-control? | Reason for exclusion | Notes |
| --- | --- | --- | --- |
| Wen, 2006 | Cohort | Antidepressant use is not in the first trimester | Exposure to SSRI defined as at least 1 SSRI prescription dispensed in the year before pregnancy; therefore, no evidence that they were actually using the SSRI during the first trimester of pregnancy |
| Wichman, 2009 | No | Antidepressant use is not in the first trimester | Cannot connect first trimester usage of SSRIs with heart defects |
| Cole, 2007 | No | Comparison group is unsuitable | The comparison group has used non-paroxetine antidepressants |
| Cole, 2007 | No | Comparison group is unsuitable | Comparison group is exposed to antidepressants |
| Colvin, 2011 | Cohort | Comparison group is unsuitable | The unexposed group is defined as not having redeemed scripts for SSRIs. Therefore, they may be exposed to non-SSRI antidepressants. |
| Ericson, 1999 | No | Comparison group is unsuitable | The comparison group has used antidepressants |
| McElhatton, 1996 | No | Comparison group is unsuitable | No comparison group |
| Scialli, 2010 | No | Comparison group is unsuitable | No comparison group |
| Warburton, 2010 | No | Comparison group is unsuitable | No comparison group; not first trimester antidepressant usage |
| Dawson, 2015 | Case-control | Did not meet requirements for inclusion from study criteria analysis | Missing outcome data |
| Einarson, 2008 | No | Did not meet requirements for inclusion from study criteria analysis | Assessment of outcome: Structured interview and physician assessment |
| Klieger-Grossmann, 2012 | Cohort | Did not meet requirements for inclusion from study criteria analysis | Follow-up also includes abortions. Missing information. P-values only, no ORs or RRs |
| Merlob 2009 | No | Did not meet requirements for inclusion from study criteria analysis | Only examining newborns with persistent cardiac murmurs; self-reported SSRI usage; unblinded assessment of outcome |
| Habermann, 2013 | No | No antidepressant usage | Antipsychotics, not antidepressants |
| Huybrechts, 2016 | Cohort | No antidepressant usage | Antipsychotics, not antidepressants |
| Ozturk, 2016 | Cohort | No antidepressant usage | Antipsychotics, not antidepressants |
| Petersen, 2016 | Cohort | No antidepressant usage | Only cardiac outcome data is for Lithium |
| Reis, 2008 | No | No antidepressant usage | Antipsychotics, not antidepressants |
| Vigod, 2015 | No | No antidepressant usage | Antipsychotics, not antidepressants |
| Yaris, 2005 | No | No antidepressant usage | Psychotropics, not antidepressants |
| Djulus, 2006 | No | No cardiac defect outcomes measured | No cardiac outcomes |
| Einarson, 2001 | No | No cardiac defect outcomes measured | Missing cardiac outcomes |
| Einarson, 2009 | Cohort | No cardiac defect outcomes measured | Outcome assessed via interview and corroboration of records. Missing information. No ORs or RRs or P-values. No cardiac defect outcomes |
| Nembhard, 2017 | No | No cardiac defect outcomes measured | Assessing genotype of parents whose children have congenital heart defects. Not measuring the correlation between SSRIs and congenital heart defects. Therefore, unsuitable. |
| Nishigori, 2017 | Cohort | No cardiac defect outcomes measured | No cardiac outcomes documented |
| Pearson, 2007 | No | No cardiac defect outcomes measured | No cardiac outcomes |
| Ramos, 2008 | No | No cardiac defect outcomes measured | No info for septal defects in the control group; outcome is all major congenital malformations, not congenital heart defects specifically |
| Reefhuis, 2014 | Case-control | No cardiac defect outcomes measured | Cases were assigned by the presence of any congenital malformations, not congenital heart defects specifically. The ORs reported for heart defects are from reviews of other studies. |
| Richardson, 2019 | Case-control | No cardiac defect outcomes measured | No cardiac outcomes documented |
| Roca, 2011 | No | No cardiac defect outcomes measured | Cases are assigned by maternal disease, not congenital heart defects |
| Sivojelezova, 2005 | Cohort | No cardiac defect outcomes measured | Missing outcome data; no numbers for cardiac outcomes |
| Anonymous, 2006 | No | Not a case-control or cohort study | Not a case-control or cohort study |
| Anonymous, 2011 | No | Not a case-control or cohort study | Not a case-control or cohort study |
| Cuzzell, 2006 | No | Not a case-control or cohort study | Not a case-control or cohort study |
| Hendrick, 2003 | No | Not a case-control or cohort study | Not a case-control or cohort study |
| Jimenez-Solem, 2014 | No | Not a case-control or cohort study | Review of his previous studies |
| Johnson, 1997 | No | Not a case-control or cohort study | Not a case-control or cohort study |
| Malm, 2005 | No | Not a case-control or cohort study | Not a case-control or cohort study |
| Morrow, 1972 | No | Not a case-control or cohort study | Not a case-control or cohort study |
| Nordeng, 2014 | No | Not a case-control or cohort study | Review of several studies. |
| Pastuszak, 1993 | No | Not a case-control or cohort study | Not a case-control or cohort study |
| Reiff-Eldridge, 2000 | No | Not a case-control or cohort study | Not a case-control or cohort study |
| Sim, 1972 | No | Not a case-control or cohort study | Not a case-control or cohort study |
| Urato, 2014 | No | Not a case-control or cohort study | Systematic review and meta-analysis |
| Williams, 2005 | No | Not a case-control or cohort study | Not a case-control or cohort study |
| Wilton, 1998 | No | Not a case-control or cohort study | Not a case-control or cohort study |
| Winterfeld, 2015 | No | Not a case-control or cohort study | Not a case-control or cohort study |
| Zuccotti, 2012 | No | Not a case-control or cohort study | Not a case-control or cohort study |
| Alwan, 2007 | Case-control | Overlapping study | Data is from the National Birth Defects Prevention Study; overlaps with Alwan 2010 |
| Jimenez-Solem, 2012 | Cohort | Overlapping study | Like the Furu et al 2015 study, this study also uses the Danish medical birth registry. However, this study only investigates SSRIs as a group, not as individuals, like the Furu 2015 study |
| Knudsen, 2014 | Cohort | Overlapping study | Uses the Danish EUROCAT Register from 1995-2008 and only investigates SSRIs as a class. The Jordan et al 2016 study uses the same register, along with the EUROCAT registers from Wales and Norway to study SSRIs as individuals and as an entire class. The Jordan et al 2016 study also has a larger number of study participants |
| Kornum 2010 | Cohort | Overlapping study | From Danish medical birth registry 1991 - 2007 (15y). The Furu 2015 study is from the same registry (1996 - 2010) = 14 y. Despite the shorter time period in the Furu study, additional data was collated from other countries' registries and therefore the number of participants in the Furu study are larger than those in this study |
| Louik, 2007 | Case-control | Overlapping study | Data is from the Slone Epidemiology Birth Defects Study; overlaps with Louik 2014 |
| Malm, 2011 | Cohort | Overlapping study | Uses data from the National birth registry from Finland 1996 - 2006. The Furu 2015 study uses data from the same period from the national registry. The Furu 2015 study is also combined with data from other registries and it has a larger number of study participants |
| Pedersen, 2009 | Cohort | Overlapping study | This study data overlaps with the Furu 2015 study data from Denmark. Additionally, the Furu 2015 study has 7 years more data from Denmark, investigates additional countries and more individual SSRIs. |
| Petersen, 2016 | Cohort | Overlapping study | Uses data from The Health Improvement Network 1990 - 2001. Ban et al 2014 also uses this data, but over a longer time period. As such, it has a higher number of study participants |
| Reis, 2010 | Cohort | Overlapping study | Uses data from Swedish health registries from 1995 - 2007. The Furu 2015 study uses data from this same register from 1996 - 2010, in combination with data from other countries. Therefore, the Furu 2015 study uses data from a larger period of time and also has more study participants |
| Sun, 2019 | Case-control | Overlapping study | Data is taken from the Danish medical birth registry 1995 - 2008. Furu 2015 uses data from 1996 - 2010 from the same registry (over a wider time period), also investigating SSRIs, but as a prospective cohort study (a stronger study design than this retrospective case-control study) |
| Wemakor, 2015 | Case-control | Overlapping study | This case-control study uses EUROCAT data from Norway, Wales and Denmark. Jordan et al 2016 also uses this data, but with a larger number of study participants and as a prospective cohort study, which is a stronger study design than this retrospective case-control study |
| Wogelius, 2006 | Cohort | Overlapping study | Uses data from the Danish medical birth registry from 1991 - 2003; this overlaps with the data used by Furu 2015 |